However, no improvement in graft patency was noted with further LDL reduction to <70 mg/dL (P=1.00).83 Extensive evidence exists supporting the use of high-inten- sitystatintherapyforsecondarypreventionamongpatientswith clinical atherosclerotic cardiovascular disease.82 Although the data are sparse in the CABG literature, the recent ACC/AHA cholesterol guideline statement recommended high-intensity statin therapy for the majority of patients who have clinical atherosclerotic cardiovascular disease, which would include nearly all patients who have previously undergone CABG.82 The only exception to this recommendation relates to patients >75 years of age, given the potential for drug-drug interactions in this population and because few patients of this age were included in the high-intensity statin trials.82 Notwithstanding the new recommendations, little experience has accrued with the use of high-intensity statin therapy early after CABG as it relates to patient compliance and side effects. Moreover, it remains unclear whether high-intensity statin therapy early after CABG will improve graft patency or slow the process of vein graft disease compared with usual moderate statin doses, highlighting the need for further research on the subject. 